Please login to the form below

Not currently logged in
Email:
Password:

Ono Pharmaceuticals

This page shows the latest Ono Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Ono faces steep price cut for Opdivo in Japan

Ono faces steep price cut for Opdivo in Japan

Ono faces steep price cut for Opdivo in Japan. Japanese regulator proposes 50% cut after drug’ s population growth exceeds initial projections. ... Japan has followed through on plans for an out-of-cycle price cut for Ono Pharmaceuticals' cancer drug

Latest news

  • Immunotherapy and future directions in oncology Immunotherapy and future directions in oncology

    To date, three immune checkpoint inhibitors reached the market: ipilimumab (Yervoy, Bristol-Myers Squibb), nivolumab (Opdivo, Bristol-Myers Squibb and Ono Pharmaceuticals), and pembrolizumab (Keytruda, Merck &Co.) - all three marketed for

  • Ipragliflozin beats diabetes rivals to Japanese approval Ipragliflozin beats diabetes rivals to Japanese approval

    The Japanese regulatory authorities have cleared ipragliflozin under the Suglat trade name for the treatment of type 2 diabetes, beating rivals Ono Pharmaceuticals/AstraZeneca and Johnson &Johnson who have filed their

  • Promising new agents for multiple myeloma Promising new agents for multiple myeloma

    Chemotherapy: Proteasome inhibitors. There are currently two approved proteasome inhibitors - bortezomib (Velcade, Millennium Pharmaceuticals) and carfilzomib (Kyprolis, Ono Pharmaceutical) - both of which are administered intravenously. ... A third

  • Developing drugs to conquer cancer Developing drugs to conquer cancer

    One example is the impressive results from a large phase I study of BMS-936558 (anti-PD-1; Bristol-Myers Squibb/Ono Pharmaceuticals), a fully human anti-PD-1 monoclonal antibody

  • J&J signs $1.1bn deal with Genmab for cancer antibody

    as well as J&J's own Velcade (bortezomib) which was developed with Takeda unit Millennium Pharmaceuticals. ... Things are looking increasingly crowded, however, as there is a fairly fertile crop of drug candidates coming through development, most notably

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics